AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
chlortetracycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 624 | 57-62-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A TETRACYCLINE with a 7-chloro substitution.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 59.66 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.52 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.381 | Moderate | 0.77 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.811 | Moderate | 0.77 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.119 | 10^-6 cm/s | Moderate | 0.77 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.208 | uL/min/10^6 cells | Moderate | 0.77 |
| dppb | Dog plasma protein binding (% unbound) | 59.990 | % | Moderate | 0.77 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 39.070 | % | Moderate | 0.77 |
| herg | hERG pIC50 | 4.590 | pIC50 | Moderate | 0.77 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.173 | uL/min/10^6 cells | Moderate | 0.77 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.105 | uL/min/mg protein | Moderate | 0.77 |
| hppb | Human plasma protein binding (% unbound) | 53.790 | % | Moderate | 0.77 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3A,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CG,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 78 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAP3K2,MAPK12,MAPK7,STK33,SYK,TEK,TGFBR1,TTK | 19 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 2.748 | Moderate | 0.77 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 5.649 | Moderate | 0.77 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 5.781 | Moderate | 0.77 | |
| mppb | Mouse plasma protein binding (% unbound) | 48.680 | Moderate | 0.77 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.152 | Moderate | 0.77 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.77 | |
| pppb | Pig plasma protein binding (% unbound) | 47.700 | % | Moderate | 0.77 |
| rat-kpuu-brain | Rat brain Kpuu | 0.008 | % | Moderate | 0.77 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.496 | uL/min/10^6 cells | Moderate | 0.77 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.370 | % | Moderate | 0.77 |
| rppb | Rat plasma protein binding (% unbound) | 37.220 | % | Moderate | 0.77 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 914.113 | uM | Moderate | 0.77 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 23, 1950 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A01AB21 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
| ATC | D06AA02 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Tetracycline and derivatives |
| ATC | J01AA03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
| ATC | S01AA02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:22986 | calcium ionophore |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35820 | antiprotozoal drug |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:39442 | fluorescent probe |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
Related Drugs by ATC class:
A01AB Antiinfectives and antiseptics for local oral treatment 22 drugs
D06AA Tetracycline and derivatives 3 drugs
J01AA Tetracyclines 13 drugs
S01AA Antibiotics 27 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Trachoma | indication | 2576002 | DOID:11265 |
| Neonatal conjunctivitis | indication | 34298002 | DOID:9699 |
| Minor Bacterial Skin Infections | indication | ||
| Blepharoconjunctivitis | off-label use | 68659002 | DOID:2456 |
| Bacterial conjunctivitis | off-label use | 128350005 | DOID:9700 |
| Ocular rosacea | off-label use | 200933006 | |
| Meibomianitis | off-label use | 309779001 | |
| Infective blepharitis | off-label use | 312219000 | |
| Bacterial keratitis | off-label use | 314557000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Maintenance of weight gains in the presence of respiratory disease | Indication |
| Cattle | Bacterial enteritis caused by Escherichia coli | Indication |
| Cattle | Bacterial enteritis caused by Salmonella spp | Indication |
| Cattle | Bacterial pneumonia caused by Pasteurella spp | Indication |
| Cattle | Bacterial pneumonia caused by Histophilus spp | Indication |
| Cattle | Bacterial pneumonia caused by Klebsiella spp | Indication |
| Cattle | To reduce the incidence of liver abscesses | Indication |
| Cattle | Anaplasmosis caused by Anaplasma marginale | Indication |
| Chickens | Infectious synovitis caused by Mycoplasma synoviae | Indication |
| Chickens | Escherichia coli infections | Indication |
| Chickens | Prevention of coccidiosis caused by Eimeria tenella | Indication |
| Chickens | Prevention of coccidiosis caused by E necatrix | Indication |
| Chickens | Prevention of coccidiosis caused by E acervulina | Indication |
| Chickens | Prevention of coccidiosis caused by E maxima | Indication |
| Chickens | Prevention of coccidiosis caused by E brunetti | Indication |
| Chickens | Prevention of coccidiosis caused by E mivati | Indication |
| Chickens | Chronic respiratory disease caused by Mycoplasma gallisepticum | Indication |
| Chickens | Chronic respiratory disease caused by Escherichia coli | Indication |
| Ducks | Cholera caused by Pasteurella multocida | Indication |
| Psittacine Birds | Psittacosis caused by Chlamydia psittaci | Indication |
| Sheep | Reducing the incidence of (vibrionic) abortion caused by Campylobacter fetus infection | Indication |
| Swine | Reduction of the incidence of cervical abscesses | Indication |
| Swine | Bacterial swine enteritis | Indication |
| Swine | Maintenance of weight gains in the presence of atrophic rhinitis | Indication |
| Swine | Bacterial pneumonia caused by Pasteurella multocida | Indication |
| Swine | Reduction in the incidence of cervical lymphadenitis (jowl abscesses) caused by group E Streptococci | Indication |
| Swine | Proliferative enteropathies (ileitis) caused by Lawsonia intracellularis | Indication |
| Swine | Leptospirosis caused by Leptospira pomona | Indication |
| Swine | Reducing the incidence of (vibrionic) abortion caused by Campylobacter fetus infection | Indication |
| Turkeys | Infectious synovitis caused by Mycoplasma | Indication |
| Turkeys | Hexamitiasis caused by Hexamita meleagridis | Indication |
| Turkeys | Control of complicating bacterial organisms associated with bluecomb | Indication |
| Turkeys | Reduction of mortality caused by paratyphoid caused by Salmonella typhimurium | Indication |
| Cattle | Maintenance of weight gains in the presence of respiratory disease | Indication |
| Cattle | Bacterial enteritis caused by Escherichia coli | Indication |
| Cattle | Bacterial enteritis caused by Salmonella spp | Indication |
| Cattle | Bacterial pneumonia caused by Pasteurella spp | Indication |
| Cattle | Bacterial pneumonia caused by Histophilus spp | Indication |
| Cattle | Bacterial pneumonia caused by Klebsiella spp | Indication |
| Cattle | Reduction of the incidence of liver abscesses | Indication |
| Cattle | Anaplasmosis caused by Anaplasma marginale | Indication |
| Chickens | Infectious synovitis caused by Mycoplasma synoviae | Indication |
| Chickens | Reduction of mortality caused by Escherichia coli infections | Indication |
| Chickens | Prevention of coccidiosis caused by Eimeria tenella | Indication |
| Chickens | Prevention of coccidiosis caused by E necatrix | Indication |
| Chickens | Prevention of coccidiosis caused by E acervulina | Indication |
| Chickens | Prevention of coccidiosis caused by E maxima | Indication |
| Chickens | Prevention of coccidiosis caused by E brunetti | Indication |
| Chickens | Prevention of coccidiosis caused by E mivati | Indication |
| Chickens | Chronic respiratory disease caused by Mycoplasma gallisepticum | Indication |
| Chickens | Chronic respiratory disease caused by Escherichia coli | Indication |
| Ducks | Cholera caused by Pasteurella multocida | Indication |
| Psittacine Birds | Psittacosis caused by Chlamydia psittaci | Indication |
| Sheep | Reducing the incidence of (vibrionic) abortion caused by Campylobacter fetus infection | Indication |
| Swine | Reduction of the incidence of cervical abscesses | Indication |
| Swine | Bacterial swine enteritis | Indication |
| Swine | Maintenance of weight gains in the presence of atrophic rhinitis | Indication |
| Swine | Bacterial pneumonia caused by Pasteurella multocida | Indication |
| Swine | Reduction in the incidence of cervical lymphadenitis (jowl abscesses) caused by group E Streptococci | Indication |
| Swine | Proliferative enteropathies (ileitis) caused by Lawsonia intracellularis | Indication |
| Swine | Leptospirosis caused by Leptospira pomona | Indication |
| Swine | Reducing the incidence of (vibrionic) abortion caused by Campylobacter fetus infection | Indication |
| Turkeys | Infectious synovitis caused by Mycoplasma | Indication |
| Turkeys | Hexamitiasis caused by Hexamita meleagridis | Indication |
| Turkeys | Control of complicating bacterial organisms associated with bluecomb | Indication |
| Turkeys | Reduction of mortality caused by paratyphoid caused by Salmonella typhimurium | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Aureomix S 40/40 Granular | Zoetis Inc. | 2 |
| Aureo S 700 Granular, Aureo S 700 | Zoetis Inc. | 2 |
| Amprol Plus and Aureomycin | Zoetis Inc. | 3 |
| AUREOMIX S 700-A | Zoetis Inc. | 2 |
| AUREOMIX S 700-D | Zoetis Inc. | 2 |
| Aureomix S 700-G | Zoetis Inc. | 2 |
| Aureomix S 700-E | Zoetis Inc. | 2 |
| Aureomix 700-F | Zoetis Inc. | 2 |
| Aureomix S 700-C | Zoetis Inc. | 2 |
| AUREOMIX S 700-B | Zoetis Inc. | 2 |
| AUREOMIX S 700-H | Zoetis Inc. | 2 |
| Deccox and Aureomycin | Zoetis Inc. | 2 |
| COYDEN plus CTC | Huvepharma EOOD | 2 |
| ChlorMax 50, ChlorMax 65, ChlorMax 70, ChlorMax 100, Micro CTC | Zoetis Inc. | 1 |
| Chloratet 100, Chloratet 50, Chloratet 90 | Pharmgate Inc. | 1 |
| Aureomycin 50 Granular, Aureomycin 50 Granular A, Aureomycin 70 Granular, Aureomycin 80 Granular, Aureomycin 90 Granular, Aureomycin 90 Meal, Aureomycin 100 Granular | Zoetis Inc. | 1 |
| PfiChlor 50, PfiChlor 70, PfiChlor 100 | Zoetis Inc. | 1 |
| Chloronex Sulmet | Huvepharma EOOD | 2 |
| Chlortetracycline Hydrochloride Tablets | Huvepharma EOOD | 1 |
| Bulk Chlortetracycline Hydrochloride | Zoetis Inc. | 1 |
| Aureomycin Soluble Powder | Zoetis Inc. | 1 |
| Aureomycin Soluble Oblets | Huvepharma EOOD | 1 |
| CHLORTETRACYCLINE SOLUBLE POWDER | Pharmgate Inc. | 1 |
| Fermycin Soluble | Phibro Animal Health Corp. | 1 |
| CHLORTET-SOLUBLE-O | Pharmgate Inc. | 1 |
| Chloronex | Pharmgate Inc. | 1 |
| Chlortetracycline hydrochloride soluble powder | Pharmgate Inc. | 1 |
| Calf Scour Boluses, Chlortetracycline Pneumonia | Cronus Pharma Specialities India Private Limited | 1 |
| CTC Bisulfate Soluble Powder | Cronus Pharma Specialities India Private Limited | 1 |
| CLTC 10, CLTC 20, CLTC 30, CLTC 50, CLTC 70 | Phibro Animal Health Corp. | 1 |
| CLTC 50 MR, CLTC 100 MR | Phibro Animal Health Corp. | 1 |
| Robenz and Aureomycin | Zoetis Inc. | 2 |
| PfiChlor 100S | Zoetis Inc. | 1 |
| Aureomycin / Coban | Zoetis Inc. | 2 |
| Pennchlor S 40/40 | Pharmgate Inc. | 2 |
| Pennchlor 50, Pennchlor 50 G, Pennchlor 90 G, Pennchlor 100 G, Pennchlor 100 Hi-Flo | Pharmgate Inc. | 1 |
| Bio-Cox/Aureomycin | Zoetis Inc. | 2 |
| Aureomycin and Cattlyst | Zoetis Inc. | 2 |
| Denagard plus CTC | Elanco US Inc. | 2 |
| BMD and ChlorMax | Zoetis Inc. | 2 |
| Chlormax and Deccox | Zoetis Inc. | 2 |
| Aureomycin / Deccox | Zoetis Inc. | 2 |
| Aureomycin and Bovatec | Zoetis Inc. | 2 |
| MGA and Aureomycin | Zoetis Inc. | 2 |
| MGA and Bovatec and Aureomycin | Zoetis Inc. | 3 |
| Aureo S 700 and Bovatec | Zoetis Inc. | 3 |
| Aureomycin / Sacox | Huvepharma EOOD | 2 |
| Chlortetracycline HCL Soluble Powder | Quo Vademus LLC | 1 |
| BMD-25, -30, -40, -50, -60, or -75 / Aureomycin -50, -70, -80, -90 or -100 | Zoetis Inc. | 2 |
| Bio-Cox / ChlorMax | Zoetis Inc. | 2 |
| ChlorMax / Sacox | Zoetis Inc. | 2 |
| ChlorMax / Coban | Zoetis Inc. | 2 |
| Pennchlor 64 | Pharmgate Inc. | 1 |
| Pennchlor S | Pharmgate Inc. | 2 |
| Pennchlor / Coban | Pharmgate Inc. | 2 |
| Pennchlor / Denagard | Pharmgate Inc. | 2 |
| Pennchlor / Bio-Cox | Pharmgate Inc. | 2 |
| BMD Pennchlor | Pharmgate Inc. | 2 |
| Pennchlor / Deccox | Pharmgate Inc. | 2 |
| Aureomycin | Pharmgate Inc. | 1 |
| Deracin 50 Meal, Deracin 90 Meal, Deracin 100 Meal | Pharmgate Inc. | 1 |
| Deracin plus Bovatec | Pharmgate Inc. | 2 |
| Deccox plus Deracin | Pharmgate Inc. | 2 |
| Denagard and Deracin | Pharmgate Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.26 | acidic |
| pKa2 | 6.96 | acidic |
| pKa3 | 7.57 | acidic |
| pKa4 | 11.92 | acidic |
| pKa5 | 12.66 | acidic |
| pKa6 | 13.29 | acidic |
| pKa7 | 9.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 4 | CHEMBL | |||||
| Major prion protein | Surface antigen | WOMBAT-PK | |||||||
| Protein-arginine deiminase type-4 | Enzyme | IC50 | 4 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019677 | VUID |
| N0000147769 | NUI |
| D02255 | KEGG_DRUG |
| 1306093 | RXNORM |
| C0008293 | UMLSCUI |
| CHEBI:27644 | CHEBI |
| CTC | PDB_CHEM_ID |
| CHEMBL404520 | ChEMBL_ID |
| CHEMBL2146063 | ChEMBL_ID |
| D002751 | MESH_DESCRIPTOR_UI |
| DB09093 | DRUGBANK_ID |
| 13537 | IUPHAR_LIGAND_ID |
| 236 | INN_ID |
| 64-72-2 | SECONDARY_CAS_RN |
| WCK1KIQ23Q | UNII |
| 54675777 | PUBCHEM_CID |
| 4431 | MMSL |
| 618 | MMSL |
| 002741 | NDDF |
| 003592 | NDDF |
| 373509001 | SNOMEDCT_US |
| 57538001 | SNOMEDCT_US |
| 7737009 | SNOMEDCT_US |
| 96319006 | SNOMEDCT_US |
| 96320000 | SNOMEDCT_US |
| CHEMBL2146100 | ChEMBL_ID |
| CHEMBL2106006 | ChEMBL_ID |
| 57122-99-3 | SECONDARY_CAS_RN |
| 27823-62-7 | SECONDARY_CAS_RN |
| 4017878 | VANDF |
| 4019677 | VANDF |
Pharmaceutical products:
None